Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Synchrony Financial (SYF) Price & Performance

Adaptive Biotechnologies CorpTrade
Synchrony FinancialTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Synchrony Financial — how do they compare? Adaptive Biotechnologies Corp trades at $24.94 (market cap $4.04B), while Synchrony Financial trades at $79.32 (market cap $25.53B). The key difference: Synchrony Financial is far larger — about 6.3× Adaptive Biotechnologies Corp's market cap, and Synchrony Financial pays a 1.73% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTSYF
Market Cap
$4.04B$25.53B
Sector
HealthFinancials
52-Week High
$25.45$88.47
52-Week Low
$12.30$63.78
Enterprise Value
$4.10B
Dividend Yield
1.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.

Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.

Synchrony Financial

Synchrony Financial (SYF) trades at $78.78, up 0.75% today, with strong technical momentum as the stock tests resistance near $79. Recent earnings beats, including Q2 2026 EPS of $2.59 versus $2.14 expected, highlight robust fundamentals. The company maintains a net income margin of 23.4% and a low P/E of 8.05, signaling potential undervaluation. A new partnership with Stripe for CareCredit expansion and a $0.34 dividend reinforce positive business developments.

SYF presents a compelling investment case with analyst consensus bullish—62.5% buy ratings and an $86.33 price target imply ~10% upside. Risks include rising interest expenses of $4.14B and a projected negative net cash flow in 2026. Aggressive share buybacks and stable credit trends support upside, but macroeconomic pressures on consumer spending warrant monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Synchrony Financial

Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.

Read more on SYF